132,870 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Purchased by Stonepine Capital Management LLC

Stonepine Capital Management LLC purchased a new stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 132,870 shares of the company's stock, valued at approximately $417,000. Stonepine Capital Management LLC owned 0.13% of Acelyrin as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP bought a new position in shares of Acelyrin during the 4th quarter valued at approximately $371,000. Wellington Management Group LLP purchased a new position in Acelyrin in the fourth quarter valued at approximately $567,000. Franklin Resources Inc. lifted its stake in Acelyrin by 36.9% in the third quarter. Franklin Resources Inc. now owns 128,591 shares of the company's stock valued at $634,000 after purchasing an additional 34,642 shares during the last quarter. Barclays PLC lifted its stake in Acelyrin by 208.8% in the third quarter. Barclays PLC now owns 96,408 shares of the company's stock valued at $475,000 after purchasing an additional 65,188 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its stake in Acelyrin by 21.9% in the fourth quarter. Wells Fargo & Company MN now owns 52,014 shares of the company's stock valued at $163,000 after purchasing an additional 9,332 shares during the last quarter. Institutional investors own 87.31% of the company's stock.

Acelyrin Stock Up 2.2%

Acelyrin stock traded up $0.05 during trading on Wednesday, hitting $2.28. The stock had a trading volume of 4,076,500 shares, compared to its average volume of 1,237,707. The stock has a market cap of $229.97 million, a price-to-earnings ratio of -0.93 and a beta of 1.07. Acelyrin, Inc. has a 1 year low of $1.85 and a 1 year high of $7.25. The stock's 50 day moving average is $2.39 and its two-hundred day moving average is $2.93.

Acelyrin (NASDAQ:SLRN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.40. As a group, equities research analysts anticipate that Acelyrin, Inc. will post -2.53 EPS for the current fiscal year.

Insider Transactions at Acelyrin

In other news, CEO Mina Kim sold 17,986 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the transaction, the chief executive officer now owns 671,753 shares in the company, valued at approximately $1,840,603.22. This represents a 2.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.60% of the stock is owned by corporate insiders.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.